Albus Health Device Detects Early Warning Signs of Child Asthma Attacks Up To Five Days Before Onset
Albus Health Device Detects Early Warning Signs of Child Asthma Attacks Up To Five Days Before Onset Research presented at...
Clinical Trial
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for...
Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258
Calgary, Alberta--(Newsfile Corp. - November 28, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is...
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
Mangosteen Marvel MangoSoothe Outperforms Leading Joint Health Supplements
Naiad's MangoSoothe changed joint health with its single-ingredient mangosteen formula, showing results in just five days. Clinical studies demonstrate 50%...
Rakovina Therapeutics Announces Private Placement Offering
The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the OfferingVANCOUVER, British Columbia, Nov....
Patient Engagement Technology Market to grow by USD 37.41 Billion from 2024-2028, driven by rising chronic disease cases and AI’s impact on market trends – Technavio
NEW YORK, Nov. 27, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global patient engagement technology...
Top NY Plastic Surgeon Dr. Rubinstein Chosen to Train New Advanced BOTOX(R) Cosmetic Technique for Platysma Bands After FDA Approval
Renowned expert Dr. Rubinstein to train practitioners on new BOTOX® technique for smoother neck contours in New York. NEWBURGH, NY...
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and...
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers...
Prenetics Announces Third Quarter 2024 Financial Results
Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand...
Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives
SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic...
ALK’s pivotal phase 3 trial in children published in reputable scientific journal
The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy...
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the...
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,...
Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic
NORTHAMPTON, MA / ACCESSWIRE / November 26, 2024 / Women - especially teen girls and young women living in sub-Saharan...
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions...
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular...
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~~ Expects Early Interim Data in 1Q 2025 ~ SAN DIEGO, CA...